Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Abstract Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yannan Zhao, Cheng Liu, Yingjian Zhang, Chengcheng Gong, Yi Li, Yizhao Xie, Bingrui Wu, Zhongyi Yang, Biyun Wang
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2018
Sujets:	Metastatic Breast Cancer Patients Total Lesion Glycolysis (TLG) Intra-tumor Heterogeneity Heterogeneity Parameter Metabolic Tumor Volume Medicine R Science Q
Accès en ligne:	https://doaj.org/article/53499fd6cb6449139ee0ba36d9607cf7
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Documents similaires